Herceptin - For metastatic breast cancer tumors that overexpress the HER2 protein

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 1998年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1046 / 1047
页数：2
相关论文
共 50 条
  • [41] HER2/Neu-Herceptin biomarker development for theranostic management of breast cancer patients
    Luther, E.
    Glazyrin, A.
    Geddie, W.
    Eliason, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 67 - 67
  • [42] Noninvasive optical imaging of HER2 inhibition during trastuzumab (herceptin) treatment of breast cancer
    Gee, Michael S.
    Upadhyay, Rabi
    Bergquist, Henry
    Alencar, Herlen
    Josephson, Lee
    Weissleder, Ralph
    Mahmood, Umar
    CANCER RESEARCH, 2006, 66 (08)
  • [43] Clinical efficacy & toxicity of Herceptin in metastatic breast-cancer patients with tumours that overexpress Her-2 Ben: the Australian expanded access program.
    Chan, A
    Saab, J
    Quayle, JA
    Adams, K
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S114 - S114
  • [44] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
    Lee, Jin Sun
    Yost, Susan Elaine
    Stiller, Tracey
    Blanchard, Suzette
    Padam, Simran
    Katheria, Vani
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Himat
    Sedrak, Mina S.
    Waisman, James Ross
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne E.
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer
    Kong, Sun-Young
    Nam, Byung-Ho
    Lee, Keun Seok
    Kwon, Youngmee
    Lee, Eun Sook
    Seong, Moon-Woo
    Lee, Do Hoon
    Ro, Jungsil
    CLINICAL CHEMISTRY, 2006, 52 (08) : 1510 - 1515
  • [46] The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.
    Kong, SY
    Kwon, Y
    Lee, DH
    Lee, JS
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 48S - 48S
  • [47] Trastuzumab (Herceptin) in the treatment of breast cancer with HER2 overexpressionTrastuzumab (Herceptin) en el tratamiento del cáncer de mama con sobreexpresión de HER2
    Joel M. Salazar Cavazos
    Juan Francisco González Guerrero
    William O. Brito Villanueva
    Joan Albanell Mestres
    José M. Baselga Torres
    Revista de Oncología, 2001, 3 (4): : 172 - 182
  • [48] Activating HER2 missense mutations in HER2-negative metastatic breast cancer
    Shah, Mirat
    Ensminger, Jennifer
    Wang, Chenguang
    Ali, Siraj
    Chung, Jon
    Lauring, Josh
    Park, Ben Ho
    Stearns, Vered
    CANCER RESEARCH, 2020, 80 (04)
  • [49] Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
    Xiaoying Chen
    Cheryl Li
    Reginald Ewesuedo
    Donghua Yin
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 667 - 667
  • [50] Issues and controversies in the treatment of HER2 positive metastatic breast cancer
    Surabhi Amar
    Alvaro Moreno-Aspitia
    Edith A. Perez
    Breast Cancer Research and Treatment, 2008, 109 : 1 - 7
12345